Countdown to BioMarin (BMRN) Q4 Earnings: Wall Street Forecasts for Key Metrics

Core Viewpoint - BioMarin Pharmaceutical (BMRN) is expected to report a significant decline in quarterly earnings per share, while revenues are projected to increase year-over-year, indicating mixed performance expectations from analysts. Earnings Estimates - Analysts predict quarterly earnings of $0.25 per share, reflecting a decline of 72.8% compared to the same period last year [1] - There has been a downward revision of 2.3% in the consensus EPS estimate over the last 30 days [2] Revenue Forecasts - Total revenues are forecasted to be $829.66 million, representing a year-over-year increase of 11% [1] - Analysts expect 'Revenues- Net product revenues' to be $813.04 million, indicating a change of +10.5% year-over-year [4] - 'Revenues- Royalty and other revenues' are estimated at $13.32 million, reflecting a year-over-year change of +14.1% [5] Product-Specific Revenue Estimates - 'Revenues- Net Product Revenues- NAGLAZYME' is projected to reach $123.94 million, indicating a change of +12.7% from the prior-year quarter [5] - 'Revenues- Net Product Revenues- VIMIZIM' is estimated at $201.47 million, reflecting a change of +5.5% from the prior-year quarter [6] - 'Revenues- Net Product Revenues- VOXZOGO' is expected to be $262.31 million, indicating a year-over-year change of +26.1% [7] - 'Revenues- Net Product Revenues- KUVAN' is projected to reach $20.82 million, reflecting a decline of -25.7% from the year-ago quarter [7] - 'Revenues- Net Product Revenues- ALDURAZYME' is estimated at $44.95 million, indicating a change of +15.3% from the prior-year quarter [7] - 'Revenues- Net Product Revenues- BRINEURA' is forecasted to be $47.51 million, reflecting a year-over-year change of -1% [8] - 'Revenues- Net Product Revenues- ROCTAVIAN' is expected to reach $7.58 million, indicating a change of -31.1% from the prior-year quarter [8] Market Performance - Shares of BioMarin have shown returns of +8.9% over the past month, outperforming the Zacks S&P 500 composite's -0.8% change [8] - BioMarin holds a Zacks Rank 3 (Hold), suggesting it is expected to mirror overall market performance in the near future [8]